Rafael Blanco-Domínguez

Rafael Blanco-Domínguez

Auto-generated profile, based on publicly available information

Rafael Blanco-Domínguez

Gulbenkian Institute for Molecular Medicine 1 , Lisbon

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SMSofia Mensurado
Sofia Mensurado
RBRafael Blanco-Domínguez
Rafael Blanco-Domínguez
BSBruno Silva-Santos
Bruno Silva-Santos

1 November 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RBRafael Blanco-Domínguez
Rafael Blanco-Domínguez
HFHortensia de la Fuente
Hortensia de la Fuente
Cristina RodriguezCristina Rodriguez
Cristina Rodriguez
LMLaura Martín-Aguado
Laura Martín-Aguado
RSRaquel Sánchez-Díaz
Raquel Sánchez-Díaz
PMPilar Martín
Pilar Martín
Increasing evidence has pointed to the important function of T cells in controlling immune homeostasis and pathogenesis after myocardial infarction (MI), although the underlying molecular mechanisms remain elusive. In this study, a broad analysis of immune markers in 283 patients revealed significant CD69 overexpression on Tregs after MI. Our results in mice showed that CD69 expression on Tregs increased survival after left anterior descending (LAD) coronary artery ligation. Cd69–/– mice developed strong IL-17+ γδT cell responses after ischemia that increased myocardial inflammation and, consequently, worsened cardiac function. CD69+ Tregs, by induction of AhR-dependent CD39 ectonucleotidase activity, induced apoptosis and decreased IL-17A production in γδT cells. Adoptive transfer of CD69+ Tregs into Cd69–/– mice after LAD ligation reduced IL-17+ γδT cell recruitment, thus increasing survival. Consistently, clinical data from 2 independent cohorts of patients indicated that increased CD69 expression in peripheral blood cells after acute MI was associated with a lower risk of rehospitalization for heart failure (HF) after 2.5 years of follow-up. This result remained significant after adjustment for age, sex, and traditional cardiac damage biomarkers. Our data highlight CD69 expression on Tregs as a potential prognostic factor and a therapeutic option to prevent HF after MI.

11 April 2024 in Blood
Verified
Journal Article
Open access
PDF file
SMSofia Mensurado
Sofia Mensurado
CCCarolina Condeço
Carolina Condeço
DSDiego Sánchez-Martínez
Diego Sánchez-Martínez
SSSara Shirley
Sara Shirley
RCRui M. L. Coelho
Rui M. L. Coelho
BSBruno Silva-Santos
Bruno Silva-Santos
Relapsed or refractory acute myeloid leukemia (AML) remains a major therapeutic challenge. We have recently developed a Vδ1+ γδ T cell–based product for adoptive immunotherapy, named Delta One T (DOT) cells, and demonstrated their cytolytic capacity to eliminate AML cell lines and primary blasts in vitro and in vivo. However, the molecular mechanisms responsible for the broad DOT-cell recognition of AML cells remain poorly understood. Here, we dissected the role of natural killer (NK) cell receptor ligands in AML cell recognition by DOT cells. Screening of multiple AML cell lines highlighted a strong upregulation of the DNAM-1 ligands, CD155/pulmonary vascular resistance (PVR), CD112/nectin-2, as well as the NKp30 ligand, B7-H6, in contrast with NKG2D ligands. CRISPR-mediated ablation revealed key nonredundant and synergistic contributions of PVR and B7-H6 but not nectin-2 to DOT-cell targeting of AML cells. We further demonstrate that PVR and B7-H6 are critical for the formation of robust immunological synapses between AML and DOT cells. Importantly, PVR but not B7-H6 expression in primary AML samples predicted their elimination by DOT cells. These data provide new mechanistic insight into tumor targeting by DOT cells and suggest that assessing PVR expression levels may be highly relevant to DOT cell–based clinical trials.

1 May 2017 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RSRaquel Sánchez-Díaz
Raquel Sánchez-Díaz
RBRafael Blanco-Dominguez
Rafael Blanco-Dominguez
SLSandra Lasarte
Sandra Lasarte
KTKaterina Tsilingiri
Katerina Tsilingiri
EMEnrique Martín-Gayo
Enrique Martín-Gayo
PMPilar Martín
Pilar Martín
Thymus-derived regulatory T (tTreg) cells are key to preventing autoimmune diseases, but the mechanisms involved in their development remain unsolved. Here, we show that the C-type lectin receptor CD69 controls tTreg cell development and peripheral Treg cell homeostasis through the regulation of BIC/microRNA 155 (miR-155) and its target, suppressor of cytokine signaling 1 (SOCS-1). Using Foxp3-mRFP/cd69+/− or Foxp3-mRFP/cd69−/− reporter mice and short hairpin RNA (shRNA)-mediated silencing and miR-155 transfection approaches, we found that CD69 deficiency impaired the signal transducer and activator of transcription 5 (STAT5) pathway in Foxp3+ cells. This results in BIC/miR-155 inhibition, increased SOCS-1 expression, and severely impaired tTreg cell development in embryos, adults, and Rag2−/− γc−/− hematopoietic chimeras reconstituted with cd69−/− stem cells. Accordingly, mirn155−/− mice have an impaired development of CD69+ tTreg cells and overexpression of the miR-155-induced CD69 pathway, suggesting that both molecules might be concomitantly activated in a positive-feedback loop. Moreover, in vitro-inducible CD25+ Treg (iTreg) cell development is inhibited in Il2rγ−/−/cd69−/− mice. Our data highlight the contribution of CD69 as a nonredundant key regulator of BIC/miR-155-dependent Treg cell development and homeostasis.

16 April 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
RBRafael Blanco-Domínguez
Rafael Blanco-Domínguez
LBLeandro Barros
Leandro Barros
MCMariana Carreira
Mariana Carreira
MPManon van der Ploeg
Manon van der Ploeg
CCCarolina Condeço
Carolina Condeço
BSBruno Silva-Santos
Bruno Silva-Santos
Colorectal cancer (CRC) remains a challenge for current immunotherapies. Vδ1+ γδ T cells offer a promising alternative because of their HLA-I-independent cytotoxicity and natural tissue tropism. We developed Delta One T (DOT) cells, a Vδ1+ γδ T cell-based adoptive cell therapy clinically explored for hematological malignancies but not yet for solid tumors. Here we demonstrate the capacity of DOT cells to target CRC cell lines and patient-derived specimens and organoids in vitro and to control tumor growth in an orthotopic xenograft model of CRC. Notwithstanding, we found tumor-infiltrating DOT cells to exhibit a dysregulated balance of cytotoxic and inhibitory receptors that paralleled that of endogenous Vδ1+ tumor-infiltrating lymphocytes and limited their cytotoxicity. To maximize efficacy, we unveil two strategies, increasing targeting through upregulation of NKG2D ligands upon butyrate administration and blocking the checkpoints TIGIT and PD1, which synergistically unleashed DOT cell cytotoxicity. These findings support DOT cell-based combinatorial approaches for CRC treatment.

28 May 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
MCMariana Carreira
Mariana Carreira
LBLeandro Barros
Leandro Barros
RCRafael M Cruz
Rafael M Cruz
CFCristina Ferreira
Cristina Ferreira
CCCarla Costa
Carla Costa
RBRafael Blanco-Domínguez
Rafael Blanco-Domínguez
Immunotherapy has transformed cancer treatment, yet its efficacy in solid tumors, and particularly in colorectal cancer (CRC), remains limited by insufficient infiltration of endogenous or adoptively transferred immune cells. Our group developed Delta One T (DOT) cells, an allogeneic Vδ1-enriched γδ T-cell product with demonstrated efficacy in CRC models, but the critical mechanisms guiding their tumor homing are unclear. Here we show that DOT cells acquire a specific chemokine receptor profile during expansion to support tumor infiltration, characterized by prominent CXCR3 expression. Importantly, CXCR3 ligands (CXCL9–11) are expressed by CRC cell lines and primary tumors, and correlate with Vδ1 T cell infiltration and DOT-cell recruitment. CXCR3 signaling is critical for DOT-cell migration in vitro and in vivo, as pharmacologic blockade reduced tumor homing, whereas enhancing CXCR3 ligand expression increased DOT-cell infiltration and improved tumor control. These findings establish CXCR3 signaling as a key regulator of DOT-cell trafficking and a prime target to boost γδ T cell-based immunotherapies for CRC.